BLUE – Bluebird Bio Inc is focused on developing and commercializing drugs based on gene therapy to treat patients with genetic diseases and cancer.
BLUE – Bluebird Bio Inc
|Fundamentals||Previously closed at||47.72|
|Analysts opinion||Bluebird Bio announced that its ongoing phase 2 study evaluating the product candidate “Lenti-D” for the treatment of cerebral adrenoleukodystrophy (CALD) will be presented today at the American Academy of Neurology (AAN) Annual Meeting. The news for the investigational drug Lenti- D seems to be positive, with all patients remaining free of MFDs, and consistent safety-profile. The revenues for the stock is expected to be reported on May 4th, and analysts estimate EPS at $-1.19. Technically, bluebird has formed a double-bottom chart pattern, and is expected to be bullish.|
|Sentiments||Also, Deutsche Bank AG and Bank of America Corp DE have boosted their stakes in BLUE and investor sentiment seems to be bullish.|
|Social Media Pulse||The stock has 100% higher chatter than usual.|